THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION.
Start Date: Sep 21, 2023
End Date: Sep 30, 2026
82% of period elapsed
Loading contract activity data...
Modification ID | Description | Action Date | Obligated Amount | Action Type |
|---|---|---|---|---|
Subaward # | Subawardee | Description | Amount | Action Date |
|---|---|---|---|---|